A. Jordan, R. Scholz, P. Wust, R. Felix (Berlin, Germany).
"Magnetic fluid hyperthermia (MFH) A new experimental anticancer treatment
with AC magnetic field excited biocompatible nanoparticles"
Dr. Jordan starts with the statement that in the early ‘50's, a few U.S. groups tried
to perform hyperthermia with magnetizable microparticles. Clinical application of this
form of treatment was far behind the horizon. In the early ‘90's, the potential of
stable suspension of superparamagnetic nanoparticles was for the first time randomized
from the physical point of view and also its biological efficacy in vitro and in vivo was
recognized. He also mentioned in laboratory study that early C3H mammary carcinoma was
treated with MFH for 30 minutes at 47o C and found that 44% of animals had complete tumor
control for 30 days. This was an excellent presentation and opening a new field for
treatment of malignant tumor with MFH and especially with nanoparticles which could be
transported in the cells and give intra cellar hyperthermia. So this will open a new area
of research for the future.
P. Pontiggia, E. Pontiggia, G.F. Baronzio (Pavia, Italy).
These were two papers presented together.
"Interleukin 2 induction by in vitro hyperthermia"
"Non thermal effect of heating. A new modality of treatment"
In the first paper, Dr. Pontiggia presented an interesting study which attempted to induce
autologous IL to interleukin 2 heating the peripheral blood lympho-monocytes after
exposure to low concentration of rIL2. Ten patients with different primaries were treated
with single sessions of lymphocytapheresis. The collected lympho-monocytes were incubated
at 37o C and 41o C for 24 hours. Before incubation, a small quantity of rIL2 (180 U.I./ml)
was added. Nine out of 10 patients responded to treatment and showed the response to
exposure of 41o C was significantly better than 37o C. Only a single patient failed to
respond to treatment. This patient was affected by non-Hodgkin's lymphoma.
The second paper was a new hyperthermic device INDIBA HCR 900, a radiofrequency with 0.5
Mhz external asymmetric applicators. Fifty-five patients were treated in a total of 198
sessions of therapy. Each session lasted about 45 minutes. There was no adverse effect of
secondary complications. The results showed that thermal effect was not homogeneous and
was completely different in different depth and the rate of response in all the patients
was 50%. There was some clinical improvement of the tumor response. An author stated that
the possible immunological stimulation could be responsible for this response.
J. Porcheron, J.N.Talabard, C. Breton, K. Szavnicki, J.N. Balique
(St. Ethiene, France).
"Intra-peritoneal chemo-hyperthermia for peritoneal carcinomatosis:
Original modeling, clinical tolerance, results study"
The author presented 30 patients who had been treated with intra-peritoneal
chemo-hyperthermia. He found that this method offers a very uniform intra-peritoneal
hyperthermia and chemotherapy with minimal risk. However, one of 30 patients died
postoperatively two weeks after the therapy due to respiratory complications and chronic
bronchitis. This was a group of different patients with different primaries and all
tolerated treatment. The author concludes that this form of treatment can be given for a
patient for whom intra-peritoneal chemotherapy hyperthermia would be recommended.
Dr. Haim I. Bicher, Ralph S. Wolfstein, Tressia Keen, M. N. Sylvia
Carter (Valley Cancer Institute, Los Angeles, CA, U.S.A.).
"Thermoradiotherapy in breast cancer--treatment of localized inflammatory
recurrence"
Dr. James Haim Bicher reviewed his work since 1984. He has treated 132 patients with 90%
response and 72% had complete response. He mentioned that he started a clinical trial
involving 37 fields in 12 patients. Each field received 2000 to 4000 cGy with external
beam bolus radiation with 25 hyperthermia. These were inflammatory carcinoma of the
breast. The total response was 90% and complete response 81%. He reported one recurrence
in complete response, and three first degree of thermal burn. He found no correlation
between the response rate and the radiation dose.
Bahram Goliaei and Samideh Khoei (Institute of Biochemistry and
Biophysics, University of Tehran, Tehran, I.R. Iran.)
"The thermal dose-response characteristics of human prostate cancer cell
lines PC3 and LNCaP"
Dr. Goliaei stated that hyperthermia is being widely used for treatment of prostate
cancer. He tried to use two cell lines PC3 and LNCaP on monolayer cultures treated with
intervals of 0-180 minutes with temperature of 40-45o C, and he found that temperature of
42o C slowed down the growth rate of the cell line and found the plating efficiencies of
both cell lines declined. Also, he found that there was a difference of heat sensitivity
to each cell line. He extrapolated this one on clinical use. He mentioned that some of the
tumors of prostate may not respond to hyperthermia and some may.
Gilly, F.N., Beaujard-Sayag A.C., Grandclement E., Glehen O.,
Francois Y., Garbit F., Sadeghi-Looyeh B., Bienvenu J., Vignal J. (Lyon, France).
"Peritonectomy procedure (PP) associated with intraperitoneal
chemo-hyperthermia (PCH) in abdominal cancer with peritoneal carcinomatosis (PC): Phase
I-II study"
Dr. Gilly reported his previous work which was 90 patients with digestive tract and 60
patients with ovarian cancer. He reported that his review showed that intraperitoneal
chemo-hyperthermia is increasing the survival and controlling local disease in Stage I
& II. The patients with Stage III & IV, that means those patients have residual
granulation with diameter larger than 5.0 mm in the peritoneal cavity, would not benefit
from a course of therapy. He reviewed 15 patients (eight female, five male) Stage I &
II with different pathology of ovarian, large bowel, and small bowel. He reported there
were no intraoperative deaths during the therapy or 6-9 hours after therapy, no
postoperative deaths, two long postoperative ileus, and one jejunal fistula. He concluded
that the results show that intraoperative chemo-hyperthermia therapy is a feasible, safe
procedure with low morbidity. He mentioned that at the present time, they are studying a
phase II trial to see the efficacy of this form of treatment.
E.D. Hager, H. Strama, D. Hohmann, H. Dziambor (Bad
Bergzabern, Germany).
"Prevention of cystectomy of recurrent bladder carcinoma by intravesical
hyperthermic perfusion chemotherapy (IVHP)"
After giving the background of treatment of bladder cancer, Dr. Hager's presentation was
the prevention of cystectomy of recurrent bladder cancer by intravesical hyperthermia
perfusion chemotherapy. He reviewed seven patients (6 male, 1 female) treated with
intravesical hyperthermia chemotherapy with mitomycin C (MMC). He noticed that this
reduced the relapse time. Also, he noticed some downstaging of tumor. He concluded that
intravesical hyperthermia with combination of MMC is a safe procedure and could be done to
decrease the relapse rate markedly and also downstaging and downgrading the tumor and
cystectomy can be prevented. He also mentioned that further trial will be necessary to
confirm this finding.
E.D. Hager, C. Popa, D. Hohmann, D. Gallenbeck, M. Stephan, H.
Dziambor (Bad Bergzabern, Germany).
"Deep hyperthermia with RF for patients with liver metastases from
colorectal cancer"
Dr. Hager reported a single arm study of 80 patients with progressive liver metastases
from colorectal treated with deep heat radiofrequency 13.56 MHz RF. They also received a
palliative chemotherapy during the followup which showed hyperthermia has an influence in
the overall survival of the patient with liver metastases suffering from colorectal
cancer. He mentioned that the randomized study should be done to confirm this finding.
M.M.J. Oosthuizen and M.J. Nel (Johannesburg, South Africa).
"Heat shock does not promote multi-drug resistance but sensitise
oesophageal cancer cells when exposed to anticancer drugs"
Dr. Oosthuizen gave an excellent presentation by telling that chaperone proteins, also
known as stress- or heat-shock proteins, are essential for cell survival when cells are
subjected to environmental stress. Then he took the oesophageal cell cancer line WHCO-3
and subjected those to repetitive of drug therapy and then sublethal heat-shock.
Interestingly, he found that the result indicated heat-shock protein sensitises
oesophageal cells toward drug rather than rendering them drug resistant.
The XXI ICHS Meeting, was hosted by Valley Cancer Institute, James Haim I Bicher, M.D.,
president
Top of page james haim bicher md james haim bicher md
Search Engine Optimization by SeOS
